ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behçet’s Syndrome"

  • Abstract Number: L14 • ACR Convergence 2024

    A Withdrawal Study of Colchicine in Behçet Syndrome

    Basak Sirin1, Sinem Nihal Esatoglu2, Hasan Yazıcı3 and Gulen Hatemi4, 1Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, 3Academic Hospital, Istanbul, Turkey, 4Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey

    Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
  • Abstract Number: 2515 • ACR Convergence 2024

    Upadacitinib for Refractory Behçet’s Syndrome: A Multi-center, Prospective, Open-label, Pilot Study

    Weiyi Xia1, Jiachen Li1, Tian Liu1 and Yuhui Li2, 1Peking University People’s Hospital, Beijing, China, 2Peking University, BeiJing, China

    Background/Purpose: The aim of this prospective cohort study is to evaluate the efficacy and safety of Janus kinase (JAK) inhibitor upadacitinib in refractory Behçet’s Syndrome…
  • Abstract Number: 2517 • ACR Convergence 2024

    Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behçet’s Syndrome

    Betul Sarac1, Ayse Kalkanci2, Esra Kilic2, Elif Ayca Sahin2, Yesim Ozguler3 and Gulen Hatemi3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Gazi University, Faculty of Medicine, Department of Medical Microbiology, Ankara, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Gut, oral and genital mucosa microbiome studies in Behçet’s syndrome have shown heterogeneous results including reduced bacterial diversity and decrease in butyrate-producing bacteria. A…
  • Abstract Number: 2518 • ACR Convergence 2024

    Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

    Yesim Ozguler1, Olivier Manches2, Didar Ucar3, Ziyan Lin2, Alireza Khodadadi-Jamayran2, Aristotelis Tsirigos2, Gulen Hatemi1 and Johannes Nowatzky4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2NYU Grossman School of Medicine, New York, NY, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
  • Abstract Number: 2522 • ACR Convergence 2024

    Anticoagulant Treatment May Decrease the Relapse Rate in Pulmonary Arterial Involvement of Behçet’s Disease When Added After the First Event

    Kerem Abacar1, Ayşe Elif Boncukcuoğlu1, Aysun Aksoy2, Derya Kocakaya1, Çagatay Cimşit1, Haner Direskeneli3 and Fatma Alibaz Öner3, 1Marmara University, istanbul, Turkey, 2Alaaddin Keykubat University, Antalya, Turkey, 3Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey

    Background/Purpose: Vascular inflammation in Behcet’s Disease (BD) is one of the most important causes of mortality due to pulmonary artery involvement (PAI) or Budd-Chiari syndrome.…
  • Abstract Number: 2524 • ACR Convergence 2024

    Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis

    Sooah Kim1, Ye Ji Jung2, Joong Kyong Ahn3 and Jiwon Hwang4, 1Environment Science & Biotechnology, Jeonju University, Jeonju, Republic of Korea, 2Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea, 3Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 4Internal Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea

    Background/Purpose: Oral manifestations can be the initial indicators of systemic diseases such as Behcet’s disease (BD) and Sjogren’s syndrome (PSS). The frequency and presentation of…
  • Abstract Number: 0150 • ACR Convergence 2024

    The Characteristics of a Northern Israeli Cohort of Patients with Behcet’s Syndrome

    Firas Sabbah1, Fadi Hassan2, Rula Daood2, Helana Jeries3, Tamar Hareuveni4, Nimer Abed5 and Mohammad E Naffaa2, 1Rheumatology Unit, Tzafon Medical Center, Poria, Israel, Tiberias, Israel, 2Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, 3Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, 4Ophthalmology department, Galilee Medical Center, Naharyia, Israel, Nahariya, Israel, 5Internal Medicine "B", Galilee Medical Center, Naharyia, Israel, Nahariya

    Background/Purpose: Behcet's syndrome (BS) is a multisystem disease that typically manifests as recurrent oral and genital ulcers, along with skin, eye, gastrointestinal, neurologic and vascular…
  • Abstract Number: 1111 • ACR Convergence 2024

    Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism

    Kessiena Aomreore, Lincoln Medical Center, New york, NY

    Background/Purpose: Autoimmune diseases are associated with a high prevalence of pulmonary embolism due to the inflammation-induced hyper coagulable state.This study aimed to analyze trends in…
  • Abstract Number: 1118 • ACR Convergence 2024

    The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study

    Muhammad Shamim1, Mazen Allouni2, Haseeb Chaudhary3 and Omer Pamuk4, 1University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, 2Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, 3Case Western Reserve University, Westlake, OH, 4University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH

    Background/Purpose: The diagnosis of Behcet’s Disease (BD) is particularly challenging in non-endemic areas because of milder disease presentations and lack of specific tests. Prior studies…
  • Abstract Number: 1633 • ACR Convergence 2024

    Arthritis Activity Significantly Affects Quality of Life in Behcet’s Disease Patients

    Koichi Sugihara1, Risa Wakiya2, Hiromi Shimada2, Taichi Miyagi2, Yusuke Ushio2, Rina Mino2, Mao Mizusaki3, Hayamasa yamaguchi3, Naoto Manabe3, Shusaku Nakashima2 and Hiroaki dobashi2, 1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa Prefecture, Japan, 2Kagawa University, Miki-cho, Kita-gun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan

    Background/Purpose: Arthritis associated with Behcet's disease (BD) has been reported to be related to patients' quality of life and associated with skin and mucosal lesions.…
  • Abstract Number: 1896 • ACR Convergence 2024

    The Prevalence, Incidence, Risk Factors and Time to Diagnosis of Behcet’s Syndrome in England: A Retrospective Nested Case Control Study in Clinical Practice Research Datalink and Hospital Episode Statistics

    Priyanka Chandratre1, Joht Chandan2, Ben Hammond3, Rasiah Thayakaran3, Samuel Cusworth3, Nicola Adderley3 and Deva Situnayake4, 1The Ottawa Hospital and Ottawa Hospital Research Institute (OHRI), Ottawa, ON, Canada, 2Institute of Applied Health Research, Birmingham, United Kingdom, 3Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom, 4Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom

    Background/Purpose: The prevalence and incidence of Behcet’s syndrome (BS) in the UK is unknown at an unselected population level. BS may be associated with phenotypically…
  • Abstract Number: 1556 • ACR Convergence 2023

    Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome

    Sinem Nihal Esatoglu1, Sabriye Guner1, Sevim Guler2, Gulen Hatemi1, Nuray Kepil3, Yusuf Ziya Erzin4, Aykut Ferhat Celik4 and Ibrahim Hatemi4, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Pathology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey

    Background/Purpose: Gastrointestinal involvement of Behçet's syndrome (GIBS) may require surgery in up to one third of the patients. We aimed to investigate the clinical characteristics,…
  • Abstract Number: 1557 • ACR Convergence 2023

    De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome

    Sinem Nihal Esatoglu1, Ozge Sonmez2, Didar Ucar3, Elif Kaymaz4, Yesim Ozguler5, Serdal Ugurlu6, Emire Seyahi1, Melike Melikoglu1, Izzet Fresko7, Vedat Hamuryudan1, Ugur Uygunoglu8, Zekayi Kutlubay9 and Gulen Hatemi1, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 4Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 6Istanbul University-Cerrahpasa, Istanbul, Turkey, 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 8Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Neurology, Istanbul, Turkey, 9Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Dermatology, Istanbul, Turkey

    Background/Purpose: Monoclonal antibody tumor necrosis factor alpha inhibitors, particularly infliximab and adalimumab, are the most commonly used biological agents in the treatment of Behçet's syndrome…
  • Abstract Number: 1558 • ACR Convergence 2023

    Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

    Didar Ucar1, Basak Ecem Bircan2, Nigar Rustamli2, Bilge Batu Oto1, Vedat Hamuryudan3, Sinem Nihal Esatoglu3 and Gulen Hatemi3, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Ophthalmology, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells (VC) on slit lamp examination at the time of diagnosis. However, the…
  • Abstract Number: 1559 • ACR Convergence 2023

    Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease

    Nuria Barroso-Garcia1, Jose Luis Martin-Varillas2, Lara Sanchez-Bilbao3, Ivan Ferraz Amaro4, Vanesa Calvo Río5, Alfredo Adán6, Inés Hernanz-Rodriguez7, Emma Beltran-Catalan8, David Diaz-Valle9, Marisa Hernandez-Garfella10, Lucia Martinez-Costa11, Manuel Diaz-Llopis12, Jose M Herreras13, Olga Maiz-Alonso14, Ignacio Torre-Salaberri15, Antonio Atanes Sandoval16, Santos Insua-Vilariño17, Raquel Almodovar18, Patricia Fanlo-Mateo19, Juan Ramon De Dios20, Angel Garcia-Aparicio21, Sergio rodriguez-Montero22, Vega Jovani23, Patricia Moya24, Eva Peña Sainz-Pardo25, Jose Luis Hernandez26 and Ricardo Blanco27, 1Hospital Universitario Puerta del Mar, Cadiz, Spain, 2Hospital de Laredo, Laredo, Spain, 3Hospital Universitario Marques de Valdecilla, Santander, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Valdecilla Hospital, Santander, Spain, 6Oftalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 7Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain, 8HOSPITAL DEL MAR, Barcelona, Spain, 9Hospital Clinico San Carlos, Madrid, Spain, 10Ophthalmology, Hospital Universitario General Valencia, Valencia, Spain, 11Ophthalmology, Hospital Universitario Doctor Peset, Valencia, Spain, 12Ophthalmology, Hospital Universitario La Fe, Valencia, Spain, 13Ophthalmology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, 14University Hospital Donostia, San Sebastian, Spain, 15Hospital Universitario de Basurto, Bilbao, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC)., A Coruña, Spain, 17Rheumatology, Hospital Universitario de Santiago de Compostela, Santiago Compostela, Spain, 18Alcorcón Foundation University Hospital, Madrid, Spain, 19Internal Medicine, Complejo Hospitalario Universitario de Navarra, Pamplona, Spain, 20Osakidetza, Vitoria, Spain, 21Hospital Universitario de Toledo, Toledo, Spain, 22Rheumatology, Hospital Universitario Virgen de Valme, Sevilla, Spain, 23Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain, 24Hospital de Santa Creu i Sant Pau, Barcelona, Spain, 25Pediatric, Hospital 12 de Octubre, Madrid, Spain, 26Rheumatology, Ophthalmology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 27Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    Background/Purpose: Cystoid macular edema (CME) is the leading cause of blindness in non-infectious uveitis. One of the most frequently associated conditions is Behçet's disease (BD)…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology